Tag Archives: Breast Cancer

Why Many Breast Cancer Patients Stop Treatment or Only Take Partial Treatment

Why Many Breast Cancer Patients Stop Treatment or Only Take Partial Treatment
Why Many Breast Cancer Patients Stop Treatment or Only Take Partial Treatment

Many women do not trust the health care system and will often forgo radiation and drug therapy after breast cancer surgery. That is according to a survey of 2,700 breast cancer patients by researchers at Johns Hopkins University. Lead author of the survey, Lorraine Dean, said over 30 percent skip treatments that are intended to kill any cancer cells that remain after surgery.

Contact Issels® for information on how combining conventional treatments with immunotherapy cancer treatment reduces the likelihood of relapse.

Doctor-patient trust is crucial

Cancer is a devastating disease and it is understandable that patients experience feelings of helplessness. It’s not just women with breast cancer who are losing trust in doctors and the health care system, it’s the general public as well. People often feel that doctors put their own financial interest ahead of patient care. When patients feel their doctors don’t listen to them or take their concerns seriously, trust begins to erode.

For the best possible outcome, it is necessary that doctors and patients have a strong bond of trust. Patients should feel comfortable being fully honest with health care providers and the doctors should always remember that a patient’s trust in them is a vital and necessary component of proper medical care. Each person’s cancer is unique and treatment should be based on the specific needs of each patient.

Personalized cancer treatment

At Issels®, we have been practicing individualized treatment for more than 60 years. We want you to make informed decisions about your cancer treatment options. Contact us today for more information on our autologous (from the patient’s own blood) non-toxic cancer treatment protocols.

Breast Cancer Patients Treated with Combination Drugs Suffer More Side Effects

New Research for Breast Cancer Studies Genes
New Research for Breast Cancer Studies Genes

One of the concerns with traditional cancer treatment is the range and severity of potential side effects that may occur. Based on the results of a recent study, patients with advanced breast cancer who are treated with a certain combination of drugs are at greater risk for serious side effects.

Fighting Cancer on Two Fronts

Some breast cancers are classified as “hormone receptor-positive.” Signals from hormones such as estrogen and progesterone reach receptors in the cancer cells, triggering further growth. Patients are commonly treated with a receptor blocker such as tamoxifen in conjunction with drugs that specifically target molecules involved in cancer cell development.

Previous research indicated that this combination therapy enabled patients to live longer without progression of the tumors. The missing piece of the puzzle was the extent to which treatment could cause side effects.

Evaluating Side Effects of Combination Therapies

A study conducted by an international research team found that patients with combination therapy were more susceptible to side effects such as fatigue, diarrhea and hyperglycemia. The degree of risk varied based on the particular drugs involved.

Scientists plan to use these results to design courses of treatment that are less likely to produce side effects. In the meantime, since these therapies do have benefits, doctors will have more information to use in prescribing and managing combination drug treatments.

Issels® Leads the Way with Non-Toxic Cancer Treatment

Personalized cancer treatment at Issels® uses a patient’s own immune cells, reducing the risk of of debilitating side effects. Contact us to learn more about our cancer vaccines and other innovative treatment programs.

Olivia Newton John Shares News of Her Breast Cancer Metastasis

Olivia Newton John Shares News of Her Breast Cancer Metastasis
Olivia Newton John Shares News of Her Breast Cancer Metastasis

Actress and singer Olivia Newton-John has campaigned to raise awareness of cancer research since she began fighting the disease in 1992. In May she made the sad announcement that her breast cancer had returned and spread to her lower spine.

The Prognosis for Metastatic Breast Cancer

Newton-John’s breast cancer is metastatic, also known as Stage IV, which refers to cancer that begins in one area of the body and spreads to other organs or tissues. It was discovered when the singer postponed a concert tour due to lower back pain that was originally thought to be sciatica.

Family and friends remain positive, and Newton-John herself plans to resume touring in August. While metastatic breast cancer is a serious issue, doctors say that Newton-John and other women with this diagnosis have reason for optimism.

Five-Year Survival by the Numbers

A recent study published in Cancer Epidemiology, Biomarkers & Prevention discovered that the five-year survival rate for women with metastatic breast cancer had reached 36 percent during the last 10 years. That number is double the five-year survival rate for women diagnosed in the early 1990s.

According to Dr. Sagar Sardesai of the Ohio State University Comprehensive Cancer Center, the healthcare community has begun thinking of metastatic breast cancer as a chronic disease. Physicians are working with patients cancer treatment programs that relieve symptoms and improve their quality of life.

Stage IV Cancer Treatment at Issels®

If you have been diagnosed with metastatic cancer, there is hope. Visit our website to read and hear testimonials from patients with Stage IV cancer in all forms who have been successfully treated with our immunotherapy programs.

Medicare Coverage for Early Detection of Cancer – What to Know

Medicare Coverage for Early Detection of Cancer - What to Know
Medicare Coverage for Early Detection of Cancer – What to Know

Navigating the ins and outs of Medicare coverage can be a challenge. Here’s what you need to know about this program and how it applies to screenings for early detection of cancer.

Do All Providers Accept Medicare?

• Participating doctors “accept assignments,” meaning they consider the amount received from Medicare along with your co-pay and deductible as payment in full, resulting in fewer out-of-pocket expenses.

• Non-participating doctors don’t always accept Medicare, so you have to pay out-of-pocket. Medicare will reimburse you for the portions they normally cover, but you still incur sizable expenses for the difference.

• Opt-out doctors don’t participate in Medicare at all, making you fully responsible for all charges.

Medicare Coverage for Cancer Screening

• Annual mammograms are covered for women aged 40 and older, while clinical breast exams (CBE) are covered every two years for women at average risk for breast cancer and once a year for those at high risk.

• Women at average risk for cervical cancer are covered for a Pap test and pelvis exam every two years, while women at high risk are covered annually.

• Colorectal screening is covered for people 50 and over based on risk factors and date of last test.

• For prostate screening, men over age 50 are covered 100 percent for an annual PSA blood test and 80 percent for a digital rectal exam (DRE).

Lung cancer screening is covered once a year if you are between 55 and 77 and have a qualifying history of smoking.

State-of-the-Art Cancer Treatment at Issels®

Our personalized cancer treatment programs have helped many of our patients achieve long-term remission. Visit our website for more information.

Breast Cancer – It’s Not a Cancer that Affects Only Women

Men Are More Likely to Get Bladder Cancer Than Women... Are You at Risk?
Not Only Women are Affected by Breast Cancer

While breast cancer is thought of primarily as a women’s disease, men are not immune. Researchers have recently identified a specific gene mutation that increases the risk of breast cancer in men.

Identifying Genetic Triggers in Male Breast Cancer

There have been a number of studies involving women and inherited BRCA (breast cancer) gene mutations. In a two-year study that was published in 2016, a joint research team from the Anthropological Survey of India and the University of Calcutta conducted a study into genetic factors behind male breast cancer.

The researchers began by collecting blood and tissue samples from several men who had been diagnosed with breast cancer. These samples were then used for gene sequencing to identify mutations that could be causing the disease.

As a result, the scientists were able to identify mutations in the BRCA2 gene that triggered the cancer growth. In addition, the study found that lifestyle and reproductive factors such as hormonal therapy and alcohol consumption can also increase risk.

Differences between Male and Female Breast Cancer

  • The lumps (or primaries) associated with breast cancer are generally smaller in men than in women, making early detection difficult.
  • BRCA2 mutation carriers are found in lymph nodes, so men don’t experience the pain that would make them seek medical care.

Genomic Testing Personalizes Immunotherapy for Cancer

Each patient is different, so immunotherapy for cancer at Issels® uses genomic and other specialized testing to create the optimum course of treatment. Contact us today to learn more about our non-toxic integrative programs such as cancer vaccines and NK cells.

New Medication May Effectively Treat Triple-Negative Breast Cancer

Cancer Survivors: A Unique Perspective on Hope
Breast Cancer Research

The term “breast cancer” encompasses several subtypes of the diseases, including triple-negative breast cancer, a more aggressive form that occurs frequently in younger women. Scientists in Ireland recently made a discovery that holds promise as an more effective treatment than chemotherapy, which is currently the only available option for this cancer subtype.

What Is Triple-Negative Breast Cancer?

Breast cancer is usually categorized by the presence or absence of three different receptors that fuel the growth of tumors. Triple-negative breast cancer lacks all three receptors, making it unresponsive to the targeted treatments often used with breast cancer.

BREAST-PREDICT is the Irish Cancer Society Collaborative Cancer Research Centre where the recent study was conducted. Researchers identified a drug called APR-246 that can prevent the growth of certain cancer cells.

APR-246 Can Mean New Hope for Breast Cancer Patients

Results of the study were published last year in the International Journal of Cancer. Naoise Synnott, the PhD student who performed the research, said she decided to focus her efforts on triple-negative breast cancer because of the lack of effective treatment for the disease.

Currently, chemotherapy is the only form of treatment available to patients with triple-negative breast cancer. Unfortunately, many of them don’t respond, leaving them to suffer the side effects of chemotherapy with no positive outcome.

Approximately one in six cases of breast cancer worldwide is diagnosed as triple-negative. The next step with APR-246 is conducting clinical trials to evaluate real-life results.

Is Immunotherapy for Cancer Right for You?

For decades, Issels® has been in the forefront of cutting-edge immunotherapy for cancer treatments. Contact us for testimonials from patients we have successfully treated for breast cancer, leukemia and other forms.